{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:47:33Z","timestamp":1789040853499,"version":"build-2803163510"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The survival rates of many cancers have significantly improved due to recent advancements in cancer screening and therapeutics. Although better cancer outcomes are encouraging, additional health challenges have surfaced, the utmost of which is the burden imposed by various cardiovascular and renal toxicities of anticancer therapies. To improve the overall outcome of patients with cancer, it is essential to understand and manage these treatment-related adverse effects. The cardiovascular side effects of antineoplastic therapies are well-known and include left ventricular dysfunction, heart failure, myocardial ischaemia, QT prolongation, arrhythmia and hypertension. Among these, hypertension is the most common complication, prevalent in about 40% of all cancer patients, yet frequently overlooked and undertreated. This review explores the intricate connection between cancer and hypertension and provides distinct approaches to diagnosing, monitoring and managing hypertension in patients with cancer. We also outline the challenges and considerations that are relevant to the care of patients receiving anticancer drugs with prohypertensive potential.<\/jats:p>","DOI":"10.1093\/ckj\/sfad195","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T16:47:49Z","timestamp":1691772469000},"page":"2336-2348","source":"Crossref","is-referenced-by-count":27,"title":["Management of hypertension in patients with cancer: challenges and considerations"],"prefix":"10.1093","volume":"16","author":[{"given":"Shubhi","family":"Pandey","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Calhoun Cardiology Center, University of Connecticut Health , Farmington , CT, USA"},{"name":"University of Connecticut School of Medicine , Farmington , CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kalaria","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Medicine , Farmington , CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester , MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7487-9340","authenticated-orcid":false,"given":"Agnes S","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Calhoun Cardiology Center, University of Connecticut Health , Farmington , CT, USA"},{"name":"University of Connecticut School of Medicine , Farmington , CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"2023120101551786900_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ackd.2021.09.011","article-title":"Onco-hypertension: an emerging specialty","volume":"28","author":"Gudsoorkar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023120101551786900_bib2","doi-asserted-by":"crossref","first-page":"379252","DOI":"10.1155\/2013\/379252","article-title":"Incidence of new-onset hypertension in cancer patients: a retrospective cohort study","volume":"2013","author":"Fraeman","year":"2013","journal-title":"Int J Hypertens"},{"key":"2023120101551786900_bib3","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"DCHv","year":"2021","journal-title":"Circ Res"},{"key":"2023120101551786900_bib4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"2023120101551786900_bib5","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/HYPERTENSIONAHA.120.14820","article-title":"Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study","volume":"75","author":"Kim","year":"2020","journal-title":"Hypertension"},{"key":"2023120101551786900_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/HYPERTENSIONAHA.113.02953","article-title":"Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women","volume":"63","author":"Sanfilippo","year":"2014","journal-title":"Hypertension"},{"key":"2023120101551786900_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"},{"key":"2023120101551786900_bib8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.13955","article-title":"Current status of angiotensin receptor blocker recalls","volume":"74","author":"Gunasekaran","year":"2019","journal-title":"Hypertension"},{"key":"2023120101551786900_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2023120101551786900_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"2023120101551786900_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2023120101551786900_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"2023120101551786900_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int"},{"key":"2023120101551786900_bib14","doi-asserted-by":"crossref","first-page":"e028050","DOI":"10.1161\/JAHA.122.028050","article-title":"Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study","volume":"12","author":"van Dorst","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2023120101551786900_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaccao.2019.11.009","article-title":"Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management","volume":"1","author":"Cohen","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2023120101551786900_bib16","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2215\/CJN.09620911","article-title":"Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors","volume":"7","author":"Knijnenburg","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023120101551786900_bib17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023120101551786900_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2023120101551786900_bib19","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"2023120101551786900_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors. JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2023120101551786900_bib21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023120101551786900_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2023120101551786900_bib23","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2023120101551786900_bib24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"key":"2023120101551786900_bib25","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib26","first-page":"821","article-title":"PI3K inhibitors: understanding toxicity mechanisms and management","volume":"31","author":"Greenwell","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"2023120101551786900_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-108-1-21","article-title":"Renal salt wasting in patients treated with cisplatin","volume":"108","author":"Hutchison","year":"1988","journal-title":"Ann Intern Med"},{"key":"2023120101551786900_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12885-017-3135-6","article-title":"Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study","volume":"17","author":"Komaki","year":"2017","journal-title":"BMC Cancer"},{"key":"2023120101551786900_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-15-156","article-title":"Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma","volume":"15","author":"Hobeika","year":"2014","journal-title":"BMC Nephrol"},{"key":"2023120101551786900_bib30","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2023120101551786900_bib31","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The Cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"2023120101551786900_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","article-title":"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses","volume":"24","author":"Lee","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2023120101551786900_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"Van De Velde","year":"2011","journal-title":"Lancet"},{"key":"2023120101551786900_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"key":"2023120101551786900_bib35","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients-a systematic review and meta-analysis","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"key":"2023120101551786900_bib36","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1161\/HYPERTENSIONAHA.122.19865","article-title":"Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis","volume":"79","author":"Minegishi","year":"2022","journal-title":"Hypertension"},{"key":"2023120101551786900_bib37","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/bloodadvances.2018030387","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"3","author":"Bohlius","year":"2019","journal-title":"Blood Adv"},{"key":"2023120101551786900_bib38","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/ijc.32917","article-title":"End of an era for erythropoiesis-stimulating agents in oncology","volume":"146","author":"Schoen","year":"2020","journal-title":"Int J Cancer"},{"key":"2023120101551786900_bib39","first-page":"14","article-title":"Etiology and management of hypertension in patients with cancer","volume":"7","author":"Mohammed","year":"2021","journal-title":"Cardiooncology"},{"key":"2023120101551786900_bib40","first-page":"319","article-title":"Cyclosporine in pediatric nephrology","volume":"12","author":"Arslansoyu Camlar","year":"2018","journal-title":"Iran J Kidney Dis"},{"key":"2023120101551786900_bib41","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbadis.2018.08.027","article-title":"Intracellular cholesterol stimulates ENaC by interacting with phosphatidylinositol\u20114,5\u2011bisphosphate and mediates cyclosporine A-induced hypertension","volume":"1865","author":"Zhai","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2023120101551786900_bib42","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1878-0261.12750","article-title":"Prevention and treatment of radiotherapy-induced side effects","volume":"14","author":"Barazzuol","year":"2020","journal-title":"Mol Oncol"},{"key":"2023120101551786900_bib43","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.ki.5002137","article-title":"Renal radiation-induced arterial stenosis","volume":"71","author":"Izzedine","year":"2007","journal-title":"Kidney Int"},{"key":"2023120101551786900_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-021-01764-y","article-title":"Radiation-induced kidney toxicity: molecular and cellular pathogenesis","volume":"16","author":"Klaus","year":"2021","journal-title":"Radiat Oncol"},{"key":"2023120101551786900_bib45","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4103\/njcp.njcp_35_19","article-title":"Paraneoplastic syndromes and oncological outcomes in renal cancer","volume":"22","author":"Ikuerowo","year":"2019","journal-title":"Niger J Clin Pract"},{"key":"2023120101551786900_bib46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/01.HYP.6.6.931","article-title":"Angiotensinogen-producing hepatocellular carcinoma","volume":"6","author":"Ueno","year":"1984","journal-title":"Hypertension"},{"key":"2023120101551786900_bib47","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1001\/archinte.1989.00390090135028","article-title":"Arterial hypertension as a paraneoplastic phenomenon in hepatocellular carcinoma","volume":"149","author":"Kew","year":"1989","journal-title":"Arch Intern Med"},{"key":"2023120101551786900_bib48","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1210\/jc.2004-2527","article-title":"Cushing's syndrome due to ectopic corticotropin secretion: twenty years\u2019 experience at the National Institutes of Health","volume":"90","author":"Ilias","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2023120101551786900_bib49","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/archinte.1993.00410060054009","article-title":"Ectopic corticotropin syndrome and small-cell carcinoma of the lung: clinical features, outcome, and complications","volume":"153","author":"Delisle","year":"1993","journal-title":"Arch Intern Med"},{"key":"2023120101551786900_bib50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.0.1500681","article-title":"Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients","volume":"150","author":"Baguet","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2023120101551786900_bib51","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2023120101551786900_bib52","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0","author":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute"},{"key":"2023120101551786900_bib53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2023120101551786900_bib54","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1365-2354.2003.00416.x","article-title":"White coat effect in breast cancer patients undergoing chemotherapy","volume":"12","author":"Costa","year":"2003","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2023120101551786900_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"2023120101551786900_bib56","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","article-title":"An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity","volume":"16","author":"Mir","year":"2011","journal-title":"Oncologist"},{"key":"2023120101551786900_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"2023120101551786900_bib58","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/jco.2005.23.16_suppl.3020","article-title":"Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G)","volume":"23","author":"Friberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40885-022-00197-3","article-title":"Risks and management of hypertension in cancer patients undergoing targeted therapy: a review","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Hypertens"},{"key":"2023120101551786900_bib60","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2023120101551786900_bib61","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2023120101551786900_bib62","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy\u2013related hypertension: a scientific statement from the american heart association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"2023120101551786900_bib63","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.22.01875","article-title":"Onco-hypertension: changing paradigm of treating hypertension in patients with cancer","volume":"41","author":"Sahni","year":"2023","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib64","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2023120101551786900_bib65","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","article-title":"Clinical approach to cardiovascular toxicity of oral antineoplastic agents","volume":"77","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023120101551786900_bib66","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023120101551786900_bib67","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"2023120101551786900_bib68","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.22.00083","article-title":"Blood pressure classification using the 2017 ACC\/AHA guideline and heart failure in patients with cancer","volume":"41","author":"Kaneko","year":"2023","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-019-0481-y","article-title":"Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK","volume":"121","author":"Plummer","year":"2019","journal-title":"Br J Cancer"},{"key":"2023120101551786900_bib70","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int"},{"key":"2023120101551786900_bib71","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","article-title":"Practical management of bevacizumab-related toxicities in glioblastoma","volume":"20","author":"Brandes","year":"2015","journal-title":"Oncologist"},{"key":"2023120101551786900_bib72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2215\/CJN.05610522","article-title":"How I manage hypertension and proteinuria associated with VEGF inhibitor","volume":"18","author":"Rashidi","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023120101551786900_bib73","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"Mckay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023120101551786900_bib74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","article-title":"Angiotensin receptors: a new role in cancer?","volume":"16","author":"Deshayes","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"2023120101551786900_bib75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"2023120101551786900_bib76","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/17843286.2018.1543827","article-title":"Abiraterone and spironolactone in prostate cancer: a combination to avoid","volume":"74","author":"Dhondt","year":"2019","journal-title":"Acta Clin Belg"},{"key":"2023120101551786900_bib77","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0022-5347(17)67001-0","article-title":"Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate","volume":"114","author":"Walsh","year":"1975","journal-title":"J Urol"},{"key":"2023120101551786900_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2011.5238","article-title":"Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate","volume":"2012","author":"Sundar","year":"2012","journal-title":"BMJ Case Rep"},{"key":"2023120101551786900_bib79","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1016\/j.clgc.2016.12.008","article-title":"Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration-resistant prostate cancer treated with abiraterone without prednisone","volume":"15","author":"Gill","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2023120101551786900_bib80","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41416-022-02036-6","article-title":"Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension","volume":"128","author":"Van Doorn","year":"2023","journal-title":"Br J Cancer"},{"key":"2023120101551786900_bib81","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1200\/JCO.2017.35.15_suppl.7525","article-title":"Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience","volume":"35","author":"Gashonia","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib82","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/annonc\/mdv369","article-title":"Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors","volume":"26","author":"Boer","year":"2015","journal-title":"Ann Oncol"},{"key":"2023120101551786900_bib83","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Gietema","year":"2000","journal-title":"Lancet"},{"key":"2023120101551786900_bib84","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/FJC.0000000000001342","article-title":"Hypertension in cancer survivors: a review of the literature and suggested approach to diagnosis and treatment","volume":"80","author":"Chuquin","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2023120101551786900_bib85","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023120101551786900_bib86","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"2023120101551786900_bib87","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"2023120101551786900_bib88","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol"},{"key":"2023120101551786900_bib89","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.116.08565","article-title":"Salt sensitivity of angiogenesis inhibition-induced blood pressure rise: role of interstitial sodium accumulation?","volume":"69","author":"Lankhorst","year":"2017","journal-title":"Hypertension"},{"key":"2023120101551786900_bib90","doi-asserted-by":"crossref","first-page":"21652","DOI":"10.1074\/jbc.M602105200","article-title":"Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function","volume":"281","author":"Wei","year":"2006","journal-title":"J Biol Chem"},{"key":"2023120101551786900_bib91","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cvr\/cvp315","article-title":"The ubiquitin-proteasome pathway and endothelial (dys)function","volume":"85","author":"Stangl","year":"2010","journal-title":"Cardiovasc Res"},{"key":"2023120101551786900_bib92","first-page":"CD008944","article-title":"Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer","volume":"3","author":"Kooijmans","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2023120101551786900_bib93","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib94","first-page":"247","article-title":"Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro","volume":"23","author":"Nuver","year":"2010","journal-title":"Oncol Rep"},{"key":"2023120101551786900_bib95","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1349-7006.2008.00696.x","article-title":"Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-kappaB dependent pathway","volume":"99","author":"Yu","year":"2008","journal-title":"Cancer Sci"},{"key":"2023120101551786900_bib96","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"key":"2023120101551786900_bib97","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2023120101551786900_bib98","doi-asserted-by":"crossref","first-page":"69477","DOI":"10.18632\/oncotarget.17704","article-title":"BRAF\/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"2023120101551786900_bib99","doi-asserted-by":"crossref","first-page":"26069","DOI":"10.1074\/jbc.M605040200","article-title":"CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1","volume":"281","author":"Isenberg","year":"2006","journal-title":"J Biol Chem"},{"key":"2023120101551786900_bib100","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib101","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.lfs.2008.08.009","article-title":"Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries","volume":"83","author":"Navarro-Dorado","year":"2008","journal-title":"Life Sci"},{"key":"2023120101551786900_bib102","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2164\/jandrol.108.007245","article-title":"The dark side of testosterone deficiency: III. Cardiovascular disease","volume":"30","author":"Traish","year":"2009","journal-title":"J Androl"},{"key":"2023120101551786900_bib103","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023120101551786900_bib104","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"2023120101551786900_bib105","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3390\/ijms24032312","article-title":"Cabozantinib, vandetanib, pralsetinib and selpercatinib as treatment for progressed medullary thyroid cancer with a main focus on hypertension as adverse effect","volume":"24","author":"H\u00f8jer Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2023120101551786900_bib106","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"2023120101551786900_bib107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1359-6101(01)00012-0","article-title":"The GDNF\/RET signaling pathway and human diseases","volume":"12","author":"Takahashi","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"2023120101551786900_bib108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12885-023-10571-5","article-title":"Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer"},{"key":"2023120101551786900_bib109","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"Lafargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023120101551786900_bib110","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2023120101551786900_bib111","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.CIR.88.3.1101","article-title":"Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation","volume":"88","author":"Kaye","year":"1993","journal-title":"Circulation"},{"key":"2023120101551786900_bib112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1389200023337964","article-title":"Interaction of cyclosporine A and the renin-angiotensin system; new perspectives","volume":"3","author":"Lassila","year":"2002","journal-title":"Curr Drug Metab"},{"key":"2023120101551786900_bib113","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol Res"},{"key":"2023120101551786900_bib114","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension","volume":"27","author":"Goodwin","year":"2012","journal-title":"Pediatr Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad195\/51307059\/sfad195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/12\/2336\/53960048\/sfad195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/12\/2336\/53960048\/sfad195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T20:56:46Z","timestamp":1701377806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/12\/2336\/7241815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":114,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,8,12]]},"published-print":{"date-parts":[[2023,11,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad195","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,8,12]]}}}